Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC599 Shigella dysenteriae type 1 oral vaccine dose-ranging trial
2004-001915-78Phase 2Completed
- Sponsor
- Institut Pasteur
- Start
- Feb 2005
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SC599 in Shigella dysenteriae infection and shigellosis (3 arms), sponsored by Institut Pasteur. Primary endpoint: Immunogenicity by IgA anti-LPS ASC response. Started Feb 2005; status: completed.
02
Drugs
SC599
03
Conditions
Shigella dysenteriae infectionshigellosis
Beyond the preview
Go deeper on 2004-001915-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001915-78.